TABLE 1.

Patients’ clinical data.

	Control	Eos CRSwNP	Non-Eos CRSwNP	Control vs Eos CRSwNP P value	Control vs Non-Eos CRSwNP P value	Eos vs Non-Eos CRSwNP P value
Subject, n	22	20	29
Sex, male, n (%)	14 (63.6)	14 (70)	15 (51.7)	NS	NS	NS
Age [years, median(IQR)]	27.5 (18.5-46.0)	38.0 (29.3-44.0)	35.0 (20.0-54.0)	NS	NS	NS
Patients with atopy, n (%)	6 (27.3)	8 (40)	7 (24.1)	NS	NS	NS
Patients with asthma, n (%)	0 (0)	2 (10)	0 (0)	NS	NS	NS
Bilateral CT score [median (IQR)]	0 (0-0)	16.0 (9.0-20.0)	17.0 (13.0-22.0)	< 0.001	< 0.001	NS
Bilateral NP score [median (IQR)]	0 (0-0)	3.0 (2.0-4.0)	3.0 (2.0- 4.0)	< 0.001	< 0.001	NS
Nasal obstruction VAS score [median (IQR)]	4 (4- 5)	6 (4.5-8)	6 (5-8)	NS	NS	NS
Nasal discharge VAS Score [median (IQR)]	0 (0- 1)	4 (2.5-6.5)	4 (2- 7.5)	< 0.001	0.003	NS
Headache VAS score [median (IQR)]	0 (0- 0)	2 (0- 4)	0 (0- 3)	0.002	0.013	NS
Facial pain VAS score [median (IQR)]	0 (0- 0.75)	0 (0- 1)	0 (0-0.5)	NS	NS	NS
Hyposmia VAS score [median (IQR)]	1 (0-2)	4 (2.5-5.5)	2 (0-6)	0.003	NS	NS
Overall discomfort VAS score [median (IQR)]	4 (2- 4.75)	5 (4-7)	5 (4-6.5)	NS	NS	NS

Eos, eosinophilic; CRSwNP, chronic rhinosinusitis with nasal polyps; Non-Eos, non-eosinophilic; NP, nasal polyps; VAS, visual analogue scale; CT, computer tomography, IQR, interquartile range.